Suche Struktur Suche
wx_img
Inquiry Form
  1. Home
  2. BMF-219

BMF-219

Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.

methyl 4-(hydroxymethyl)picolinate
methyl 4-(hydroxymethyl)picolinate
CM178754
317335-15-2
(R)-3-Boc-AMinopiperidine
(R)-3-Boc-AMinopiperidine
CM101941
309956-78-3
4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
CM1045041
2448173-20-2
4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine
4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine
CM104043
876343-10-1
4-Aminophenylboronic acid
4-Aminophenylboronic acid
CM143205
89415-43-0
4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine
4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine
CM1045040
2448173-19-9